Janet Briel

416 total citations
7 papers, 318 citations indexed

About

Janet Briel is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Janet Briel has authored 7 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 4 papers in Public Health, Environmental and Occupational Health and 3 papers in Molecular Biology. Recurrent topics in Janet Briel's work include Acute Myeloid Leukemia Research (5 papers), Acute Lymphoblastic Leukemia research (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Janet Briel is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Acute Lymphoblastic Leukemia research (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Janet Briel collaborates with scholars based in United States and Netherlands. Janet Briel's co-authors include Judith E. Karp, Steven D. Gore, Jacqueline M. Greer, Mark J. Levis, B. Douglas Smith, James R. Wright, Hetty E. Carraway, Michael A. McDevitt, Richard J. Jones and Rebecca M. Ricklis and has published in prestigious journals such as Blood, Clinical Cancer Research and The Netherlands Journal of Medicine.

In The Last Decade

Janet Briel

7 papers receiving 313 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Janet Briel United States	6	165	160	104	72	43	7	318
K Kagami Japan	10	118 0.7×	165 1.0×	71 0.7×	85 1.2×	50 1.2×	14	325
Paula de Melo Campos Brazil	11	168 1.0×	147 0.9×	69 0.7×	34 0.5×	83 1.9×	43	353
Juan Carlos Balandrán Mexico	10	95 0.6×	113 0.7×	68 0.7×	64 0.9×	27 0.6×	19	282
Andrea Zangrando Italy	8	123 0.7×	147 0.9×	95 0.9×	85 1.2×	32 0.7×	9	303
E. S. J. M. de Bont Netherlands	8	184 1.1×	148 0.9×	60 0.6×	72 1.0×	30 0.7×	13	287
Sung‐Soo Yoon South Korea	9	152 0.9×	120 0.8×	91 0.9×	34 0.5×	58 1.3×	54	272
Tony Peled Israel	8	183 1.1×	147 0.9×	103 1.0×	18 0.3×	127 3.0×	19	370
Jaime M. Guidry Auvil United States	5	92 0.6×	124 0.8×	70 0.7×	28 0.4×	25 0.6×	12	257
Michaël Broux Belgium	6	114 0.7×	128 0.8×	55 0.5×	125 1.7×	30 0.7×	6	277
Ghayas C. Issa United States	8	219 1.3×	118 0.7×	54 0.5×	44 0.6×	86 2.0×	30	291

Countries citing papers authored by Janet Briel

Since Specialization

Citations

This map shows the geographic impact of Janet Briel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet Briel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet Briel more than expected).

Fields of papers citing papers by Janet Briel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet Briel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet Briel. The network helps show where Janet Briel may publish in the future.

Co-authorship network of co-authors of Janet Briel

This figure shows the co-authorship network connecting the top 25 collaborators of Janet Briel. A scholar is included among the top collaborators of Janet Briel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet Briel. Janet Briel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Karp, Judith E., Benjamin D. Smith, Linda Resar, et al.. (2011). Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 117(12). 3302–3310. 67 indexed citations

Kanakry, Christopher G., Allan D. Hess, Christopher D. Gocke, et al.. (2010). Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 117(2). 608–617. 49 indexed citations

Karp, Judith E., Rebecca M. Ricklis, Kumudha Balakrishnan, et al.. (2007). A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 110(6). 1762–1769. 59 indexed citations

Karp, Judith E., B. Douglas Smith, Mark J. Levis, et al.. (2007). Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia. Clinical Cancer Research. 13(15). 4467–4473. 73 indexed citations

Karp, Judith E., Rebecca M. Ricklis, Jacqueline M. Greer, Janet Briel, & Mark J. Levis. (2006). Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage.. Blood. 108(11). 1963–1963. 2 indexed citations

Karp, Judith E., Antonino Passaniti, Ivana Gojo, et al.. (2005). Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias. Clinical Cancer Research. 11(23). 8403–8412. 58 indexed citations

Schouten, W. R., et al.. (1995). Pathophysiological aspects and clinical outcome of intra-anal application of isosorbide dinitrate in patients with chronic anal fissure. The Netherlands Journal of Medicine. 47(2). A25–A25. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact